Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Arctic Bioscience Remuneration Information 2024

Mar 15, 2024

3536_dirs_2024-03-15_7cfc7192-0452-4df6-8fb9-213a7a330699.html

Remuneration Information

Open in viewer

Opens in your device viewer

Arctic Bioscience - Extension of share options to members of management group

Arctic Bioscience - Extension of share options to members of management group

The Board of Directors of Arctic Bioscience AS has resolved to extend the share

option agreements for the following members of the management group: Yuming Feng

(EVP Global Business Development), Daniele Mancinelli (CTO), Hogne Hallaråker

(CSO) and Per Christian Sæbø (COO).

The exercise prices in the agreement for Feng is maintained at NOK 27,90 per

share and maintained at NOK 9,845 per share in the agreements for Mancinelli,

Hallaråker and Sæbø. The duration of the option agreements is extended until 28.

February 2025.

All options being exercised into shares during the duration period will be

subject to a "lock-in" period of 12 months from the time of exercise, where the

shares cannot be sold or transferred without the consent of the Board.

After this, Yuming Feng holds 100 000 share options via Global Nutrios

Consulting LLC, Daniele Mancinelli holds 51 570 share options, Hogne Hallaråker

holds 33 030 share options and Per Christian Sæbø holds 57 390 share options.

Notifications of transactions by persons discharging managerial responsibilities

are attached hereto.

This information is subject to the disclosure requirements pursuant to

Regulation EU 596/2014 (MAR) article 19 number 3 and the Norwegian Securities

Trading Act § 5-12.

For more information, please contact:

Christer L. Valderhaug

CEO

Phone: +47 920 84 601

E-mail: [email protected]

About Arctic Bioscience

Arctic Bioscience is a biotech company developing and commercializing

pharmaceutical and nutraceutical products based on unique bioactive marine

compounds.

The company is developing HRO350 - a novel oral drug candidate. HRO350 is being

developed for treatment of patients with mild-to-moderate psoriasis. This is a

large patient group in need of new effective medicines with beneficial safety

profile.

Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients as

well as finished goods under the ROMEGA® brand.

Arctic Bioscience is led by a highly skilled team of talents with diverse and

highly relevant background.